RxDoctor Payments DataLook up a doctor →

Elizabeth Herrington, DO

Medical Oncology · Jackson, MSNPI 1306043278

Payments from drug & device makers

$10,079in general payments, 2019–2025

Across 575 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Merck$842
  • Pfizer$654
  • Bristol Myers Squibb$631
  • Novartis$563
  • AstraZeneca$540
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,79197%
  • Education$2883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson60$1,037
Merck51$842
Pfizer43$654
Bristol Myers Squibb31$631
Novartis33$563
AstraZeneca(2 entities)26$540
Genentech USA, Inc.24$440
E.r. Squibb & Sons, L.L.C.30$436
Gilead(2 entities)18$379
Daiichi Sankyo Inc.19$347
Amgen19$283
Incyte Corporation16$267
Eisai Inc.14$254
GSK12$229
Astellas Pharma US Inc10$202
Sanofi10$188
Tersera Therapeutics LLC8$169
Lilly USA, LLC10$168
Takeda Pharmaceuticals U.S.A., Inc.9$163
Exelixis Inc.11$160
Puma Biotechnology, Inc.10$145
Regeneron Healthcare Solutions, Inc.7$119
Array Biopharma Inc7$118
Beigene USA, Inc.5$103
Coherus Oncology, Inc.6$85
Karyopharm Therapeutics Inc.4$81
Octapharma USA, Inc.4$77
Seagen Inc.5$77
EMD Serono, Inc.5$75
Genmab U.S., Inc.4$73
AbbVie3$72
Pharmacyclics LLC, An Abbvie Company4$65
Deciphera Pharmaceuticals Inc.3$63
Ipsen Biopharmaceuticals, Inc3$62
Rigel Pharmaceuticals, Inc.4$58
Acceleron Pharma, Inc.3$54
Adaptive Biotechnologies Corporation2$51
Dendreon Pharmaceuticals LLC2$51
Morphosys, US Inc.3$50
Pharming Healthcare, Inc.1$46
Verastem, Inc.3$40
Acrotech Biopharma Inc.2$36
AVEO Pharmaceuticals, Inc.2$35
Blueprint Medicines Corporation2$34
Tempus AI, Inc2$34
Boehringer Ingelheim2$33
G1 Therapeutics, Inc.2$31
Tolmar Pharmaceuticals, Inc.2$29
Kyowa Kirin, Inc.2$26
Dova Pharmaceuticals1$24
Sobi, Inc1$23
Actelion Pharmaceuticals US, Inc.1$22
Inari Medical, Inc.1$21
ADC Therapeutics America, Inc.1$20
Agios Pharmaceuticals, Inc.1$20
Recordati_rare_diseases_inc.1$20
Jazz Pharmaceuticals Inc.1$19
Emmaus Medical, Inc.1$19
Beone Medicines USA, Inc.1$18
Fennec Pharmaceuticals, Inc.1$17

How this compares

$10,079 in reported general payments places this provider in the 50th percentile of 20 medical oncology providers in Mississippi.

See all medical oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,170,669
Medicare patients
1,133
Services billed
222,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide104$1,166,994
ImbruvicaIbrutinib79$1,152,337
JakafiRuxolitinib Phosphate57$1,066,406
RevlimidLenalidomide59$965,131
CabometyxCabozantinib S-Malate29$713,205
CalquenceAcalabrutinib Maleate59$711,524
IbrancePalbociclib25$399,542
VerzenioAbemaciclib24$361,493
OjjaaraMomelotinib Dihydrochloride12$337,298
XtandiEnzalutamide11$144,385
EliquisApixaban43$28,444
Megestrol Acetate70$5,324
Imatinib Mesylate30$4,842
Letrozole291$4,481
Dexamethasone128$2,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$65$1,152,33779 claims
Incyte CorporationJakafi$267$1,066,40657 claims
Bristol Myers SquibbRevlimid$631$965,13159 claims
Exelixis Inc.Cabometyx$160$713,20529 claims
AstraZenecaCalquence$540$711,52459 claims
PfizerIbrance, Eliquis$654$427,98668 claims
Lilly USA, LLCVerzenio$168$361,49324 claims
GSKOjjaara$229$337,29812 claims
Astellas Pharma US IncXtandi$202$144,38511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 20 medical oncology providers in Mississippi.

Other medical oncology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →